UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Psoriasiform dermatitis in a person of colour with chronic hepatitis B

JEADV clinical practice, 2024-07, Vol.3 (3), p.882-886

2024

Volltextzugriff (PDF)

Therapie der Psoriasis vulgaris: Therapiestrategien für eine optimale patientenzentrierte Versorgung

Dermatologie (Heidelberg, Germany), 2024-05, Vol.75 (5), p.417-427

2024

Volltextzugriff (PDF)

Psoriasis: eine Systemerkrankung mit multiplen Behandlungsoptionen

Ästhetische Dermatologie & Kosmetologie, 2023-09, Vol.15 (4), p.34-41

2023

Volltextzugriff (PDF)

Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists

International journal of women's dermatology, 2023-12, Vol.9 (4), p.e112-e112

2023

Volltextzugriff (PDF)

Treatment of psoriasis vulgaris : Therapy strategies for optimal patient-centered care

Dermatologie (Heidelberg, Germany), 2024-05, Vol.75 (5), p.417-427

2024

Volltextzugriff (PDF)

Comparison of itch characteristics and sleep in patients with brachioradial pruritus and notalgia paresthetica: A retrospective analysis from 2 itch centers

JAAD international, 2021-03, Vol.2, p.96-97

2021

Volltextzugriff (PDF)

33047 Simultaneous improvements in skin signs and quality of life in pediatric patients with psoriasis receiving secukinumab over 52 weeks

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB109-AB109

2022

Volltextzugriff (PDF)

Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema)

Journal der Deutschen Dermatologischen Gesellschaft, 2017-06, Vol.15 (6), p.657

2017

Volltextzugriff (PDF)

Entzündliche Dermatosen im Kindes- und Jugendalter: Diagnostische und therapeutische Besonderheiten anhand der atopischen Dermatitis und der Psoriasis

Dermatologie (Heidelberg, Germany), 2024-04, Vol.75 (4), p.325-339

2024

Volltextzugriff (PDF)

53979 Comparison of different skincare regimens for patients with moderate-to-severe atopic dermatitis in addition to systemic treatment: results of a multicenter randomized controlled trial

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB165-AB165

2024

Volltextzugriff (PDF)

52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB142-AB142

2024

Volltextzugriff (PDF)

52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

Journal of the American Academy of Dermatology, 2024-09, Vol.91 (3), p.AB60-AB60

2024

Volltextzugriff (PDF)

357 The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies

British journal of dermatology (1951), 2023-01, Vol.188 (Supplement_2)

2023

Volltextzugriff (PDF)

A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Journal of the American Academy of Dermatology, 2022-01, Vol.86 (1), p.122-130

2022

Volltextzugriff (PDF)

43802 Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB128-AB128

2023

Volltextzugriff (PDF)

425 Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies

British journal of dermatology (1951), 2023-06, Vol.188 (Supplement_3)

2023

Volltextzugriff (PDF)

26860 Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB119-AB119

2021

Volltextzugriff (PDF)

Pustulobullous variant of SDRIFE (symmetrical drug‐related intertriginous and flexural exanthema)

Journal der Deutschen Dermatologischen Gesellschaft, 2017-06, Vol.15 (6), p.657-659

2017

Volltextzugriff (PDF)

Pustulobullöse Variante eines SDRIFE (symmetrical drug‐related intertriginous and flexural exanthema)

Journal der Deutschen Dermatologischen Gesellschaft, 2017-06, Vol.15 (6), p.657-659

2017

Volltextzugriff (PDF)

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

Journal of dermatology, 2024-09

2024

Volltextzugriff (PDF)

Inflammatory dermatoses in children and adolescents : Diagnosis and treatment of atopic dermatitis and psoriasis

Dermatologie (Heidelberg, Germany), 2024-04, Vol.75 (4), p.325-339

2024

Volltextzugriff (PDF)

Erfolgreiche Behandlung einer generalisierten pustulösen Psoriasis mit Certolizumab

Hautarzt, 2021-11, Vol.72 (11), p.992-995

2021

Volltextzugriff (PDF)

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

Dermatology and therapy, 2022-01, Vol.12 (1), p.203-221

2022

Volltextzugriff (PDF)

Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

Skin (Milwood, N.Y.), 2024-03, Vol.8 (2), p.s394

2024

Volltextzugriff (PDF)

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Skin (Milwood, N.Y.), 2022-11, Vol.6 (6), p.s102

2022

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

ThemaDermatitis, Atopic - Drug Therapy

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)
Berichte
(1)

Sprache

Englisch
(26)
Deutsch
(12)

Erscheinungsjahr

n.n

Thema

Dermatology
(14)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(7)
Medicine
(5)
Medicine & Public Health
(5)
Diagnosis, Differential
(4)
Allergology
(3)
Child
(3)
Immunology
(3)
Proctology
(3)
Psoriasis
(3)
Adolescent
(2)
Adult
(2)
Biologics
(2)
Cme
(2)
Dermatologic Agents - Therapeutic Use
(2)
Exanthema
(2)
Inflammatory Skin Diseases
(2)
Original Research
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Psoriasiform dermatitis in a person of colour with chronic hepatitis B

Therapie der Psoriasis vulgaris: Therapiestrategien für eine optimale patientenzentrierte Versorgung

Psoriasis: eine Systemerkrankung mit multiplen Behandlungsoptionen

Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists

Treatment of psoriasis vulgaris : Therapy strategies for optimal patient-centered care

Comparison of itch characteristics and sleep in patients with brachioradial pruritus and notalgia paresthetica: A retrospective analysis from 2 itch centers

33047 Simultaneous improvements in skin signs and quality of life in pediatric patients with psoriasis receiving secukinumab over 52 weeks

Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema)

Entzündliche Dermatosen im Kindes- und Jugendalter: Diagnostische und therapeutische Besonderheiten anhand der atopischen Dermatitis und der Psoriasis

53979 Comparison of different skincare regimens for patients with moderate-to-severe atopic dermatitis in addition to systemic treatment: results of a multicenter randomized controlled trial

52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials

52620 Long-term safety and efficacy of secukinumab over 236 weeks in children and adolescents with severe chronic plaque psoriasis: Results of a double-blind, randomized controlled phase III trial

357 The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies

A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

43802 Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab

425 Effect of upadacitinib on SCORAD intensity items: analysis from the Measure Up 1 and Measure Up 2 studies

26860 Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial

Pustulobullous variant of SDRIFE (symmetrical drug‐related intertriginous and flexural exanthema)

Pustulobullöse Variante eines SDRIFE (symmetrical drug‐related intertriginous and flexural exanthema)

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis

Inflammatory dermatoses in children and adolescents : Diagnosis and treatment of atopic dermatitis and psoriasis

Erfolgreiche Behandlung einer generalisierten pustulösen Psoriasis mit Certolizumab

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Aktive Filter

Suchergebnisse filtern